Search | IOVS | ARVO Journals

View

Showing 1 – 2 of 2

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Anti-VEGF/anti-angiopoietin-2 bispecific antibody RG7716 in diabetic macular edema: complete 36-week results from the phase 2, multicenter, randomized, active treatment-controlled BOULEVARD clinical trial

Sunil S Patel; Jayashree Sahni; Shamil Sadikhov; Meike Pauly-Evers; Piotr Szczesny; Robert Weikert

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1959. doi:

ARVO Annual Meeting Abstract September 2016

The novel bispecific monoclonal anti-VEGF/anti-Ang2 antibody RG7716 shows promise in wet age-related macular degeneration patients with suboptimal response to prior anti-VEGF monotherapy

Usha Chakravarthy; Dietmar Schwab; Patrick Cech; Mylene Giraudon; Anne Boulay; Piotr Szczesny; Paul Delmar; Jayashree Sahni

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

Advertisement